|
[1]KIM DC,JUN DW,LEE KN,et al.5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis[J].Liver Int,2013,33(4):535-543.
|
|
[2] WANG PP,XIE DY,LIANG XJ,et al.HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-k B pathway[J].PLo S One,2012,7(8):e43408.
|
|
[3]ZHU YW,GONG L,WU GJ,et al.An experimental study on in vitro transfection of mesenchymal stem cells with knocking-out TIMP-1gene by HIV-based lentiviral in rats[J].Jiangsu Med J,2015,41(11):1258-1260.(in Chinese)朱颖炜,龚镭,吴高珏,等.TIMP-1-shRNA基因体外转染大鼠骨髓间充质干细胞的实验研究[J].江苏医药,2015,41(11):1258-1260.
|
|
[4] LIU J,CHENG X,GUO Z,et al.Truncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis[J].PLo S One,2013,8(1):e53392.
|
|
[5]WANG Y,GAO J,ZHANG D,et al.New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis[J].Hepatol,2010,53(1):132-144.
|
|
[6]MARLAKA JR,PAPADOGIANNAKIS N,FISCHLER B,et al.Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis[J].Acta Paediatrica,2012,101(9):993-999.
|
|
[7]PETRASEK J,DOLGANIUC A,CSAK T,et al.Interferon regulatory factor 3 and typeⅠinterferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells[J].Hepatology,2011,53(2):649-660.
|
|
[8] KIM KA,JEONG SH.The diagnosis and treatment of primary biliary cirrhosis[J].Kor J Hepatol,2011,17(3):173-179.
|
|
[9]PENG TS,LIU YZ,YU GF.Efficacy of antioxidant N-acetylcysteine in treatment of chronic hepatitis B fibrosis[J].Guangdong Med J,2013,34(6):948-951.(in Chinese)彭土生,刘英姿,余桂芳.抗氧化剂N-乙酰半胱氨酸治疗慢性乙型肝炎肝纤维化的疗效[J].广东医学,2013,34(6):948-951.
|
|
[10] LAVINE JE,SCHWIMMER JB,van NATTA ML,et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:the TONIC randomized controlled trial[J].JAMA,2011,305(16):1659-1668.
|
|
[11]MITANI Y,IWANAGA T,NABESHIMA T,et al.Superoxide scavenging activity of pirfenidone-iron complex[J].Biochem Biophys Res Commun,2008,372(1):19-23.
|
|
[12] FNA X,ZHANG Q,LV Y,et al.Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1[J].PLo SOne,2013,8(12):e82190.
|
|
[13]YU DK,GAO Y,ZHANG CX,et al.Whole genome analysis of the effect of retinoic acid on liver fibrosis[J].Chin Pharmacol Bull,2013,29(9):1213-1216.(in Chinese)喻冬柯,高塬,张彩霞,等.全基因表达谱分析维甲酸对大鼠肝纤维化的影响[J].中国药理学通报,2013,29(9):1213-1216.
|
|
[14] FLORES-CONTRERAS L,SANDOVAL-RODRGUEZ AS,ME-NA-ENRIQUEZ MG,et al.Treatment with pirfenidone for two years decreases fibrosis,cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C[J].BMC Gastroenterol,2014,14(1):131.
|
|
[15] SRIRAM S,ROBINSON P,PI L,et al.Triple combination of siR-NAs targeting TGFβ1,TGFβR2,and CTGF enhances reduction of collagen 1 and smooth muscle actin in corneal fibroblasts[J].Invest Ophthalmol Vis Sci,2013,54(13):8214-8223.
|
|
[16] MICHAL CN,SCOTT LF.Current status of novel antifibrotic therapies in patients with chronic liver disease[J].Ther Adv Gastroenterol,2011,4(6):391-417.
|
|
[17] GARMEL BN,SEBLE L,JACK G,et al.Dissecting fibrosis:therapeutic insights from the small-molecule toolbox[J].Nat Rev Drug Discov,2015,14(10):693-720.
|
|
[18]HONG F,CHOU H,FIEL MI,et al.Antifibrotic activity of sorafenib in experimental hepatic fibrosis:refinement of inhibitory targets,dosing,and window of efficacy in vivo[J].Dig Dis Sci,2013,58(1):257-264.
|
|
[19] BARRY-HAMILTON V,SPANGLER R,MARSHALL D,et al.Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment[J].Nat Med,2010,16(9):1009-1017.
|
|
[20] KING TE,BRADFORD WZ,CASTRO-BERNARDINI S,et al.A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J].N Engl J Med,2014,370(22):2083-2092.
|
|
[21] NANTHAKUMAR CB,LEMMA S,GAULDIE J,et al.Dissecting fibrosis:therapeutic insights from the small-molecule toolbox[J].Nat Rev Drug Discov,2015,14(10):693-720.
|
|
[22] KULKARNI AA,THATCHER TH,OLSEN KC,et al.PPAR-γligands repress TGF-β-induced myofibroblast differentiation by targeting the PI3k/Akt pathway:implications for therapy of fibrosis[J].PLo S One,2011,6(1):e159009.
|
|
[23] SON MK,RYU YL,JUNG KH,et al.HS-173,a novel PI3K inhibitor,attenuates the activation of hepatic stellate cells in liver fibrosis[J].Scientif Rep,2013,3(12):3470.
|
|
[24] EVA H,SHINOBU MA,ULRIKE H,et al.Synthetic farnesoid Xreceptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor(-/-)mice[J].J Pharmacol Exp Ther,2012,343(3):556-567.
|
|
[25]GIANNITRAPANI L,SORESI M,BONDML,et al.Nanotechnology applications for the therapy of liver fibrosis[J].World J Gastroenterol,2014,20(23):7742-7251.
|
|
[26]ADRIAN JE,KAMPS JA,MEIJER DK,et al.A novel lipidbased drug carrier targeted to the non-parenchymal cells,including hepatic stellate cells,in the fibrotic livers of bile duct ligated rats[J].Biochim Biophys Acta,2007,1768(6):1430-1439.
|
|
[27]PATEL G,KHER G,MISRA A.Preparation and evaluation of hepatic stellate cell selective,surface conjugated,peroxisome proliferator-activated receptor-gamma ligand loaded liposomes[J].JDrug Target,2012,20(20):155-165.
|
|
[28]WAGN Q,WANG H,RAO L,et al.Influence of RNAi-mediated adenosine A1 and A2A receptor gene silencing on acetaldehydeinduced activation and proliferation of hepatic stellate cells in rats[J].Chin Pharmacol Bull,2015,31(1):50-55.(in Chinese)王琪,王和,饶玲,等.RNAi介导大鼠腺苷A1和A2A受体基因沉默对乙醛诱导的肝星状细胞活化增殖的影响[J].中国药理学通报,2015,31(1):50-55.
|
|
[29] KWIECINSKI M,ELFIMOVA N,NOETEL AT,et al.Expression of platelet-derived growth factor-C and insulin-like growth factorⅠin hepatic stellate cells is inhibited by miR-29[J].Lab Invest,2012,92(7):978-987.
|
|
[30]WANG JS,SUN GZ,CHEN LY,et al.Chinese medicine understanding of liver fibrosis[J].Jilin J Tradit Chin Med,2015,35(5):533-536.(in Chinese)王靖思,孙桂芝,陈兰羽,等.肝纤维化中医认识[J].吉林中医药,2015,35(5):533-536.
|
|
[31]WANG R,PAN P,WANG YJ,et al.Effects of salvianolate on expression of NF-k B and Ik Bαin rats with liver fibrosis[J].Chinese J New Drugs Clin Rem,2011,30(1):51-52.(in Chinese)王蓉,潘沛,王彧杰,等.丹参多酚酸盐对纤维化大鼠NF-κB和Ik Bα表达的影响[J].中国新药与临床杂志,2011,30(1):51-52.
|
|
[32] CHEN SR,ZOU LY,LI L,et al.The protective effect of glycyrrhetinic acid on carbon tetrachloride-induced chronic liver fibrosis in mice via upregulation of Nrf2[J].PLo S One,2013,8(1):53662-53665.
|
|
[33]YANG FR,FANG BW,LOU JS.Effects of fufang biejia ruangan pillson hepatic fibrosis in vivo and in vitro[J].World J Gastroenterol,2014,19(32):5326-5333.
|
|
[34] TAO YY,YAN XC,ZHOU T,et al.Fuzheng huayu recipe alleviates hepatic fibrosis via inhibiting TNF-αinduced hepatocyte apoptosis[J].BMC Complement Altern Med,2014,14(1):1-13.
|
DownLoad: